{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000034","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.303650+00:00","generated_at":"2026-05-21T03:02:46.364054+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Travere stockholders approve 4M-share increase in 2018 equity plan at annual meeting","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000 (71,802,001 votes for).","Ten directors elected to serve until 2026 annual meeting; all received majority votes with broker non-votes of ~4.4M.","Advisory vote on named executive officer compensation passed with 71,929,269 votes for.","Ratification of Ernst & Young as independent auditor for FY2025 approved (79,001,421 votes for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000034","json":"https://secwatch.observer/filing/0001438533-25-000034.json","markdown":"https://secwatch.observer/filing/0001438533-25-000034.md","text":"https://secwatch.observer/filing/0001438533-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000034/0001438533-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000034/tvtx-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T03:02:46.364054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}